Copd(chronic obstructive pulmonary disease)

893 views
644 views

Published on

Published in: Education, Health & Medicine
0 Comments
5 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
893
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
53
Comments
0
Likes
5
Embeds 0
No embeds

No notes for slide

Copd(chronic obstructive pulmonary disease)

  1. 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE prepared by, Likhila abraham
  2. 2. DEFINITION OF COPD  Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterized by air flow limitation that is not fully reversible. (ask.com)  Air flow limitation is usually progressive and is associated with an abnormal inflammatory response of lungs to noxious particles or gases,primarily caused by cigarette smoking.
  3. 3. COPD is a lung disease defined poor air flow as a result of break down of lung tissue or dysfunction of small air ways .primary symptom include shortness of breath ,cough ,and sputum production( medical dictionary)
  4. 4. Etiology 1.Cigerette smoking 2.Infections 3.Heriditory 4.Occupational dusts and chemicals 5.Air pollution 6.aging
  5. 5. classification of COPD definition Include chronic bronchitis ,emphysema with airflow limitation. The
  6. 6. Chronic Bronchitis
  7. 7. Chronic Bronchitis  Chronic bronchitis is defined clinically as the presence of a cough productive of sputum not attributable to other causes on most days for at least 3 months over 2 consecutive years.  Chronic inflammation of the bronchii
  8. 8. Chronic Bronchitis  Chronic nonspecific inflammation  Symptoms of cough and sputum production with or without gasping  Recurrent attacks  Chronic proceeding
  9. 9. Classification of Chronic Bronchitis Simple type of Chronic Bronchitis (without gasping) Cough Sputum expectoration Chronic Bronchitis with gasping Cough Sputum expectoration Gasping
  10. 10. Stages of Chronic Bronchitis Stages Time Courses Exacerbation In a week Chronic lag phase One month or longer stable Lasts for two months
  11. 11. Clinical manifestations Productive cough
  12. 12. breathlessness
  13. 13. Chest pain
  14. 14. Fever,fatigue
  15. 15. Weight loss and anorexia Insomnia Air hunger Cyanosis
  16. 16. Diagnosis of chronic bronchitis  History  Cough & Sputum expectoration & Gasping  Three months /per year or longer  Continuously longer than two years  Exclude other lung and heart disease If shorter than three months /per year then definite objective evidences are demanded (such as X-Ray and lung function et al.)to diagnose.
  17. 17. 1.Physical examination ( .Diminished breath sounds) 2.Pulmonary function test 3.Chest x ray 4.Blood test 5.CT
  18. 18. Obstructive Emphysema
  19. 19. Definition of Emphysema  Pulmonary emphysema (a pathological term) is characterized by abnormal,permanent enlargement of air spaces distal to the terminal bronchioles ,accompanied by destruction of their walls and hyperdistension leading to reduction in lung elastics recoil and airway obstruction.
  20. 20. Classification of Emphysema Obstructive Emphysema senile Emphysema emphysema(Physiological) without Interstitial Emphysema Obstruction Compensating Emphysema Scarred Emphysema
  21. 21. CLINICAL MANIFESTATIONS 1.Wheezing 2.cyanosis
  22. 22. Chest pain Non productive cough Fatigue malaise Weight loss
  23. 23. •Lung parenchyma (respiratory bronchioles and alveoli) Alveolar wall destruction, apoptosis of epithelial and endothelial cells. • Centrilobular emphysema: dilatation and destruction of respiratory bronchioles; most commonly seen in smokers • Panacinar emphysema: destruction of alveolar sacs as well as respiratory bronchioles; most commonly seen in alpha-1 antitrypsin deficiency
  24. 24. Normal distal lung acinus
  25. 25. Centriacinar(centrilobular) emphysema
  26. 26. Panacinar emphysema
  27. 27. spirometric classification of COPD FEV1/FVC mild <70% moderate <70% severe disease <70% Very severe < 70% FEV1%pred ≥80% 50~80% 30~50% ≤ 30%or<50% following with respiratory failure & right heart failure
  28. 28. Pathophysiology of copd
  29. 29. •Pulmonary vasculature Thickening of intima, endothelial cell dysfunction, smooth muscle pulmonary hypertension.
  30. 30. Clinical Manifestations of copd Symptoms:  Gradually progressive dyspnea is the most common presenting character. Dyspnea that is: Progressive (worsens over time) Usually worse with exercise Persistent (present every day) Described by the patient as an “increased effort to breathe,”“heaviness,” “air hunger,” or “gasping.”
  31. 31. •Chronic Cough May be intermittent and may be unproductive. •Chronic sputum production: Recurrent respiratory infection Recurrent attacks leading to cor pulmonal heart disease Unexpected Decreased weigh loss food appetite
  32. 32. Physical Signs:  Earlier period:Minimal/Nonspecific signs  Advanced Stage: *Inspection: Barrel-shaped chest , accessory respiratory muscle participate , prolonged expiration during quiet breathing. *Palpation: Weakened fremitus vocalis
  33. 33. Clinical Manifestation *Percussion : Hyperresonant depressed diaphragm, dimination of the area of absolute cardiac dullness. *Auscultation: Prolonged expiration ; reduced breath sounds; The presence of wheezing during quiet breathing Crackle can be heard if infection exist. The heart sounds are best heard over the xiphoid area.
  34. 34. Diagnostic measures
  35. 35. History and physical examination
  36. 36. Chest x-ray Chronic bronchitis Chest Radiograph(X-Ray) Non apparent abnormality Or thickened and increased of the lung markings are noted. 
  37. 37. Chest X-Ray --emphysema  Chest findings are also varible.  Marked over inflation is noted with flattend and low diaphragm  Intercostal space becomes widen  A horizontal pattern of ribs  A long thin heart shadow  Decreased markings of lung peripheral vessels
  38. 38. Chest X-Ray
  39. 39. CT(Computed tomography) : greater sensitivity and specificity for emphysema , especially for the diagnosis of bronchiectasis and evaluation of bullous disease
  40. 40. Computed Tomography
  41. 41. Labortory Examination  Blood examination In excerbation or acute infection in airway, leucocytosis may be detected. Sputum examination  streptococcus pneumonia Haemophilus influenzae Moraxella catarrhalis klebsiella pneumonia 
  42. 42. Blood gas analysis: Arterial blood gas analysis may reveal hypoxemia,particularly advanced disease. In patients with severe hypoxemia ,CO2 retention,it shows low arterial PO2 and high arterial PCO2.
  43. 43. Ecg Exercise testing with oxymetry Ecocardiogram Serum antitripsin
  44. 44. management Aim Based on the principles of  prevention of further progress of disease  preservation and enhancement of pulmonary functional capacity  avoidance of exacerbations in order to improve the quality of life.
  45. 45. TREATMENT  Stop smoking  Avoid environment pollution  Breathing retraining  Chest physiotherapy
  46. 46. Flutter mucous clearance device
  47. 47. acapella
  48. 48. Nebulization High frequency chest compression Nutritional therapy
  49. 49. Drug Therapy 1.Bronchodilators Bronchodilators are central to the symptomatic management of COPD.  improve emptying of the lungs,reduce dynamic hyperinflation and improve exercise performance .
  50. 50. Drug Therapy Bronchodilators Three major classes of bronchodilators:  β2 - agonists: Short acting: salbutamol & terbutaline Long acting :Salmeterol & formoterol  Anticholinergic agents: Ipratropium,tiotropium  Theophylline (a weak bronchodilator, which may have some antiinflammatory properties)
  51. 51. Drug Therapy 2.Glucocorticoids  Regular treatment with inhaled glucocorticoids is appropriate for symptomatic patients with anFEV1<50%pred and repeated exacerbations.  Chronic treatment with systemic glucocorticoids should be avoided because of an unfavorable benefit-torisk ratio.
  52. 52. 3. COMBINATION THERAPY Combination therapy of long acting ß2-agonists and inhaled corticosteroids show a significant additional effect on pulmonary function and a reduction in symptoms. Mainly in patients with an FEV1<50%pred
  53. 53. Drug Therapy 4.Others:  Antioxidant agents  Immunoreggulators  Alpha-1 antitrypsin augmentation  Mucolytic(mucokinetic,mucoregulator) agents  Antitussives
  54. 54. Oxygen Therapy  Oxygen -- >15 h /d Long-term oxygen therapy (LTOT) improves survival,exercise,sleep and cognitive performance in patients with respiratory failure. The therapeutic goal is to maintain SaO2 ≥ 90% and PaO2 ≥ 60mmHg at sea level and rest .
  55. 55. Long-term Oxygen therapy LTOT Indication:  For patients with a PaO2 ≤ 55 mmHg or SaO2≤88% , with or without hypercapnia  For patients with a PaO2 of 55~70 ( 60 ) mmHg or SaO2≤89% as well as pulmonary hypertension / heart failure / polycythemia (hematocrit >55%)
  56. 56. Pulmonary rehabilitation Nutrition Surgery: Bullectomy Lung volume reduction surgery Lung transplantation
  57. 57. bullectomy Lung volume reduction
  58. 58. Complications Cor pulmonale Exacerbations of copd Respiratory failure Peptic ulcer and GERD Depression
  59. 59. Clinical features Dyspnea Crackles S3 gallops Ecg changes Hepatomegaly ,splenomegaly ,ascitis
  60. 60. Management Vasodialors Digitalis Diuretics Electrolytes
  61. 61. Nursing management 1.Ineffective airway clearance 2.Imapaired gas exchange 3.Imbalnced nutrition 4.Insomnia 5.Deficient knowledge 6.anxiety

×